Searching for the needle in the haystack: deconvoluting the evolutionary dynamics of residual disease in human glioblastoma

1. Schechter AL, Stern DF, Vaidyanathan L et al. The neu oncogene: an ERB-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984; 312(5994): 513–516. 2. Finkle D, Quan ZR, Asghari V et al. HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res 2004; 10(7): 2499–2511. 3. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235(4785): 177–182. 4. Mishra R, Hanker AB, Garrett JT. Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget 2017; 8(69): 114371–114392. 5. Pillai RN, Behera M, Berry LD et al. HER2 mutations in lung adenocarcinomas: a report from the Lung Cancer Mutation Consortium. Cancer 2017; 123(21): 4099–4105. 6. Li BT, Ross DS, Aisner DL et al. HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers. J Thorac Oncol 2016; 11(3): 414–419. 7. Liu L, Shao X, Gao W et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol 2010; 5(12): 1922–1932. 8. Nakamura H, Saji H, Ogata A et al. Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in nonsmall cell lung cancer. Int J Cancer 2003; 103(1): 61–66. 9. Yoshizawa A, Sumiyoshi S, Sonobe M et al. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations. Lung Cancer 2014; 85(3): 373–378. 10. Peters S, Stahel R, Bubendorf L et al. Trastuzumab emtansine (T-DM1) in patients with previously treated HER2-overexpressing metastatic nonsmall cell lung cancer: efficacy, safety, and biomarkers. Clin Cancer Res 2019; 25(1): 64–72. 11. Dong ZY, Zhang JT, Liu SY et al. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. Oncoimmunology 2017; 6(11): e1356145. 12. Li BT, Shen R, Buonocore D et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a Phase II Basket Trial. J Clin Oncol 2018; 36(24): 2532–2537. 13. Hotta K, Aoe K, Kozuki T et al. A phase II study of trastuzumab emtansine in HER2-positive non-small cell lung cancer. J Thorac Oncol 2018; 13(2): 273–279. 14. Mazières J, Barlesi F, Filleron T et al. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann Oncol 2016; 27(2): 281–286. 15. Langer CJ, Stephenson P, Thor A et al. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group Study 2598. J Clin Oncol 2004; 22(7): 1180–1187. 16. Gatzemeier U, Groth G, Butts C et al. Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 2004; 15(1): 19–27. 17. Mazières J, Peters S, Lepage B et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013; 31(16): 1997–2003. 18. Hainsworth JD, Meric-Bernstam F, Swanton C et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from mypathway, an open-label, phase IIa multiple basket study. J Clin Oncol 2018; 36(6): 536–542. 19. Kris MG, Camidge DR, Giaccone G et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol 2015; 26(7): 1421–1427. 20. Hyman DM, Piha-Paul SA, Won H et al. HER kinase inhibition in patients with HER2and HER3-mutant cancers. Nature 2018; 554(7691): 189–194. 21. Gandhi L, Besse B, Mazieres J et al. MA04.02 neratinib 6 temsirolimus in HER2-mutant lung cancers: an international, randomized phase II study. J Thoracic Oncol 2017; 12(1): S358–S359. 22. De Grève J, Moran T, Graas MP et al. Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. Lung Cancer 2015; 88(1): 63–69. 23. Smit EF, Peters S, Dziadziuszko R et al. A single-arm phase II trial of afatinib in pretreated patients with advanced NSCLC harboring a HER2 mutation: the ETOP NICHE trial. J Clin Oncol 2017; 35(Suppl 15): 9070. 24. Lai W-CV, Lebas L, Milia J et al. Afatinib in patients with metastatic HER2-mutant lung cancers: an international multicenter study. J Clin Oncol 2017; 35(Suppl 15): 9071. 25. Wang Y, Jiang T, Qin Z et al. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. Ann Oncol 2019; 30(3): 447–455. 26. de Melo Gagliato D, Jardim DL, Marchesi MS, Hortobagyi GN. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2þ breast cancer. Oncotarget 2016; 7(39): 64431–64446. 27. Pauli C, Hopkins BD, Prandi D et al. Personalized. Cancer Discov 2017; 7(5): 462–477.